EU/3/10/808: Orphan designation for the treatment of graft-versus-host disease

Murine monoclonal antibody against CD26


On 26 November 2010, orphan designation (EU/3/10/808) was granted by the European Commission to ADIENNE S.r.l., Italy, for murine monoclonal antibody against CD26 for the treatment of graft-versus-host disease.

In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Murine monoclonal antibody against CD26
Intended use
Treatment of graft-versus-host disease
Orphan designation status
EU designation number
Date of designation
Via Galileo Galilei, 19
20867 Caponago (MB)
Tel. +39 02 4070 0445
Fax +39 02 9574 5179

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating